X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10095) 10095
Magazine Article (14) 14
Dissertation (7) 7
Newsletter (4) 4
Book Chapter (3) 3
Conference Proceeding (3) 3
Book Review (2) 2
Government Document (1) 1
Newspaper Article (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5827) 5827
male (5477) 5477
animals (5342) 5342
pyrazoles - pharmacology (4386) 4386
female (3449) 3449
pyrazoles - administration & dosage (3163) 3163
pyrazoles - therapeutic use (2717) 2717
rats (2703) 2703
pharmacology & pharmacy (2049) 2049
mice (1933) 1933
middle aged (1772) 1772
celecoxib (1746) 1746
aged (1625) 1625
pyrazoles - adverse effects (1552) 1552
dose-response relationship, drug (1428) 1428
adult (1419) 1419
piperidines - pharmacology (1318) 1318
oncology (1271) 1271
administration, oral (1255) 1255
neurosciences (1127) 1127
treatment outcome (1124) 1124
rats, sprague-dawley (992) 992
time factors (807) 807
sulfonamides - administration & dosage (764) 764
hematology (752) 752
receptor, cannabinoid, cb1 - antagonists & inhibitors (750) 750
expression (748) 748
rats, wistar (742) 742
pyrazoles (738) 738
analysis (737) 737
disease models, animal (737) 737
pyrazoles - pharmacokinetics (709) 709
sulfonamides - pharmacology (689) 689
cancer (682) 682
care and treatment (661) 661
sulfonamides - therapeutic use (651) 651
research (635) 635
aged, 80 and over (609) 609
rivaroxaban (600) 600
dabigatran (568) 568
drug therapy (559) 559
pyridones - therapeutic use (558) 558
pyridones - administration & dosage (556) 556
pyrazoles - chemistry (548) 548
cell line, tumor (545) 545
abridged index medicus (531) 531
medicine & public health (512) 512
activation (503) 503
anticoagulants (500) 500
inhibition (490) 490
mice, inbred c57bl (481) 481
anticoagulants - therapeutic use (478) 478
risk factors (477) 477
pyrimidines - pharmacology (476) 476
rimonabant (469) 469
apixaban (465) 465
brain (454) 454
cardiac & cardiovascular systems (450) 450
warfarin (449) 449
biochemistry & molecular biology (443) 443
apoptosis (441) 441
drug administration schedule (440) 440
sulfonamides - adverse effects (440) 440
anticoagulants - administration & dosage (439) 439
double-blind method (437) 437
safety (426) 426
health aspects (425) 425
pyridines - therapeutic use (422) 422
pyridones - adverse effects (415) 415
therapy (411) 411
endocannabinoids (410) 410
medicine, general & internal (410) 410
drug interactions (403) 403
prevention (394) 394
receptor, cannabinoid, cb1 - metabolism (394) 394
inflammation (391) 391
pyrimidines - administration & dosage (388) 388
efficacy (386) 386
atrial fibrillation - drug therapy (385) 385
rodents (384) 384
cyclooxygenase inhibitors - pharmacology (380) 380
pyridines - pharmacology (379) 379
pyridines - administration & dosage (377) 377
rat (377) 377
chemistry, medicinal (372) 372
cox-2 inhibitors (371) 371
dosage and administration (370) 370
cell biology (369) 369
signal transduction - drug effects (369) 369
nonsteroidal antiinflammatory drugs (366) 366
apoptosis - drug effects (362) 362
clinical trials (362) 362
pharmacology/toxicology (362) 362
anticoagulants - adverse effects (361) 361
chemotherapy (356) 356
patients (353) 353
pharmacology (352) 352
psychiatry (352) 352
adolescent (350) 350
protein kinase inhibitors - therapeutic use (350) 350
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9741) 9741
German (127) 127
Japanese (85) 85
French (59) 59
Italian (45) 45
Spanish (36) 36
Russian (31) 31
Chinese (20) 20
Czech (13) 13
Hungarian (10) 10
Norwegian (8) 8
Polish (8) 8
Swedish (8) 8
Portuguese (7) 7
Danish (5) 5
Dutch (2) 2
Finnish (2) 2
Bulgarian (1) 1
Croatian (1) 1
Korean (1) 1
Lithuanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 2014, Volume 64, Issue 11, pp. 1128 - 1139
Abstract Background Non–vitamin K oral anticoagulants (NOACs) do not require routine laboratory monitoring. However, laboratory measurement may be desirable in... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | monitoring | laboratory | apixaban | MEASURING RIVAROXABAN | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | DABIGATRAN CONCENTRATIONS | PROTHROMBIN TIME | PARTIAL THROMBOPLASTIN TIME | COAGULATION ASSAYS | IN-VITRO | FACTOR-XA INHIBITOR | PLASMA-CONCENTRATIONS | INTERNATIONAL NORMALIZED RATIO | Anticoagulants - administration & dosage | Humans | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Factor Xa Inhibitors - administration & dosage | Antithrombins - pharmacology | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - pharmacology | Factor Xa Inhibitors - pharmacology | beta-Alanine - analogs & derivatives | Pyrazoles - pharmacology | Administration, Oral | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Pyrazoles - administration & dosage | Partial Thromboplastin Time | Anticoagulants - pharmacology | Benzimidazoles - pharmacology | Drug Monitoring | Pyridones - pharmacology | Measurement | Anticoagulants (Medicine) | Vitamins | Studies | Anticoagulants | Plasma | Bibliographic literature | Laboratories | Drug therapy | Drug dosages | Bone surgery
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 2018, Volume 16, Issue 9, pp. 1891 - 1894
PROPHYLAXIS | THERAPY | THROMBOSIS | SAFETY | DISEASE | PREVENTION | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | GUIDELINE | Recurrence | Pulmonary Embolism - prevention & control | Pyrazoles - therapeutic use | Dabigatran - administration & dosage | Prospective Studies | Anticoagulants - administration & dosage | Humans | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Rivaroxaban - administration & dosage | Venous Thromboembolism - drug therapy | Factor Xa Inhibitors - administration & dosage | Neoplasms - complications | Pyridones - administration & dosage | Venous Thromboembolism - prevention & control | Multicenter Studies as Topic | Neoplasms - blood | Dalteparin - therapeutic use | Observational Studies as Topic | Venous Thrombosis - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Venous Thrombosis - drug therapy | Administration, Oral | Antithrombins - therapeutic use | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Randomized Controlled Trials as Topic | Venous Thromboembolism - etiology | Factor Xa Inhibitors - therapeutic use | Pyrazoles - administration & dosage | Patient Acceptance of Health Care | Pulmonary Embolism - etiology | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Pulmonary Embolism - drug therapy | Pyridones - therapeutic use | Hemorrhage - chemically induced | Care and treatment | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Cancer | Anticoagulants
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
The Journal of Bone & Joint Surgery, ISSN 0021-9355, 02/2013, Volume 95, Issue 4, pp. 291 - 296
BACKGROUND:Appropriate pain management affects outcome after hip fracture surgery. Although multimodal pain management is commonly used for pain control for... 
KNEE | SURGERY | DEMENTIA | TOTAL JOINT ARTHROPLASTY | DELIRIUM | HOSPITAL STAY | LOCAL INFILTRATION ANALGESIA | ELDERLY PATIENTS | ORTHOPEDICS | PUMP | CONSUMPTION | POSTOPERATIVE PAIN | Fentanyl - administration & dosage | Single-Blind Method | Hip Fractures - surgery | Pyrazoles - therapeutic use | Prospective Studies | Fentanyl - therapeutic use | Humans | Male | Adrenergic alpha-Agonists - therapeutic use | Arthroplasty, Replacement, Hip - methods | Adrenergic alpha-Agonists - administration & dosage | Epinephrine - therapeutic use | Cyclooxygenase 2 Inhibitors - therapeutic use | Statistics, Nonparametric | Aged, 80 and over | Anesthetics, Local - therapeutic use | Anesthetics, Local - administration & dosage | Oxycodone - therapeutic use | Oxycodone - administration & dosage | Cyclooxygenase 2 Inhibitors - administration & dosage | Pain Management - methods | Analgesics, Opioid - therapeutic use | Anti-Bacterial Agents - administration & dosage | Morphine - administration & dosage | Sulfonamides - administration & dosage | Ketorolac - therapeutic use | Pain, Postoperative - drug therapy | Epinephrine - administration & dosage | Patient Satisfaction | Anti-Bacterial Agents - therapeutic use | Cefmetazole - therapeutic use | Female | Drug Therapy, Combination | Analgesia, Patient-Controlled | Treatment Outcome | Amides - therapeutic use | Celecoxib | Chi-Square Distribution | Pyrazoles - administration & dosage | Sulfonamides - therapeutic use | Analgesics, Opioid - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Injections, Intra-Articular | Aged | Ketorolac - administration & dosage | Pain Measurement | Amides - administration & dosage | Morphine - therapeutic use | Cefmetazole - administration & dosage
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | L265P SOMATIC MUTATION | MULTIPLE-MYELOMA | RITUXIMAB THERAPY | IMMUNOGLOBULIN-M | MYD88 L265P | LYMPHOPROLIFERATIVE DISORDERS | LYMPHOPLASMACYTIC CELLS | INHIBITOR EVEROLIMUS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics
Journal Article
Stroke (1970), ISSN 1524-4628, 2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | cost-effectiveness | ANTICOAGULATION CONTROL | QUALITY | anticoagulation | stroke | ASPIRIN | CLINICAL NEUROLOGY | PROPHYLAXIS | atrial fibrillation | HEART-DISEASE | BENEFIT | THERAPY | intracranial hemorrhage | SCORES | PERIPHERAL VASCULAR DISEASE | UPDATE | UTILITY | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 2016, Volume 5, Issue 6, p. n/a
Journal Article
The Lancet (British edition), ISSN 0140-6736, 11/2019, Volume 394, Issue 10212, pp. 1940 - 1948
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have... 
Double-Blind Method | Humans | yes | Pyridines/administration & dosage | Male | Pyrazoles/administration & dosage | Indoles/administration & dosage | Aminophenols/administration & dosage | Cystic Fibrosis Transmembrane Conductance Regulator/genetics | Cystic Fibrosis/drug therapy | Quinolones/administration & dosage | Adolescent | Sweat/chemistry | Female | Benzodioxoles/administration & dosage | Chloride Channel Agonists/administration & dosage | Drug Therapy, Combination | Child | Pyrrolidines/administration & dosage | MEDICINE, GENERAL & INTERNAL | GUIDELINES | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Chloride Channel Agonists - adverse effects | Benzodioxoles - administration & dosage | Aminophenols - adverse effects | Indoles - administration & dosage | Sweat - chemistry | Pyridines - adverse effects | Quinolones - adverse effects | Benzodioxoles - adverse effects | Pyrazoles - adverse effects | Pyridines - administration & dosage | Pyrazoles - administration & dosage | Quinolones - administration & dosage | Indoles - adverse effects | Chloride Channel Agonists - administration & dosage | Cystic Fibrosis - genetics | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Aminophenols - administration & dosage | Cystic Fibrosis - drug therapy | Clinical trials | Cystic fibrosis | Ivacaftor | Genetic aspects | Infections | Modulators | Defects | Quality of life | Resistance | Proteins | Randomization | Chloride | Chlorides | Fibrosis | Conductance | Mutation | Safety | Sweat | Active control
Journal Article